MACROAMYLASEMIA AS A CAUSE OF HYPERAMYLASEMIA IN CLINICALLY UNCLEAR CONDITIONS—CASE REPORT

Zoran Joksimović (1), Dušan Bastać (2), Snežana Pavlović (3)

(1) INTERNIST PRACTICE "JOKSIMOVIĆ" BOR, (2) INTERNIST’S OFFICE "DR. BASTAĆ" ZAJEČAR; (3) SPECIALIST PRACTICE FOR INTERNAL MEDICINE "DR PAVLOVIĆ CARDIOLOGY" BELGRADE

Abstract: Macroamylasemia is a rare condition characterized by elevated serum amylase levels due to the existence of macromolecules - complex amylase that cannot be secreted normally by the kidneys due to their size. It is a benign condition that is usually free of marked clinical symptoms and signs. The prevalence of macroamylasemia in the population is between 1 and 2%. The main clinical significance of macromylasemia is that it is often a diagnostic problem because it requires differentiation of this condition from other causes of hyperamylasemia. Therefore, it is rational to avoid unnecessary diagnostics and treatment, which burden both the patient and the health system. Macromalasemia as a diagnosis should be considered in any patient with elevated serum amylase activity in whom serum lipase and urine amylase levels are normal. Laboratory confirmation of the diagnosis of amylasemia rests on tests: electrophoresis or polyethylene glycol precipitation test. This paper presents a patient who has been routinely treated clinically due to non-specific gastrointestinal problems. During laboratory treatment, the patient’s serum was found to have elevated amylase values. Additional diagnostics did not identify organic pancreatic diseases or other diseases that may be related to hyperamylasemia, and by calculating the ratio of renal amylase clearance to creatinine clearance of less than 1%, we conclude that it is most likely a macroamylasemia. Specific treatment was not required. The patient comes for a check-up once every 6 months.

INTRODUCTION:
Amylase is an amylolytic enzyme that helps digestion in the intestines by hydrolyzing polysaccharides to smaller molecules. In humans, there is α-amylase, which in healthy individuals originates mostly from the pancreas and salivary glands, but in clinically insignificant amounts from other organs (liver, kidneys, fallopian tubes, muscles, etc.). It can be found in two basic forms, the so-called isoenzymes - synthesized in the pancreas (pancreatic or P-isomylase) and non-pancreatic origin (salivary - salivary or S-isomylase). It is common to have low levels of amylase in the blood or urine. But if the pancreas or salivary glands are damaged, the level of amylase in the blood or urine increases. Serum amylase is elevated in at least 75% of cases of pancreatitis; Rarely, serum amylase may be normal, even if massive pancreatic necrosis occurs [1]

The detailed pathways of serum amylase metabolism have not yet been fully elucidated. Decreased metabolic clearance - renal failure may be the cause of elevated serum amylase levels. People who have had a nephrectomy or have kidney failure have an average serum amylase level that is 50% higher than healthy individuals. Therefore, it can be assumed that the kidneys play a major role in amylase metabolism. However, the kidney is not the only organ responsible for removing amylase in humans. The extrinsic mechanisms of amylase clearance are not clearly defined. Since high serum amylase levels are also observed in liver necrosis and cirrhosis, the liver is thought to play a role in amylase metabolism [2] Many conditions have been reported to cause hyperemylasemia. Although hyperamylasemia is usually assumed to be a consequence of the release of serum amylase by the diseased organ, the precise relationship between hyperemylasemia and pathological conditions is not entirely clear. Hyperamylasemia is most often the result of: pancreatitis or mumps, decreased metabolic clearance of amylase or amylase released from a damaged organ (outside the pancreas and salivary glands).
Acute or chronic pancreatitis is associated with an increase in type P isoamylase. Other causes of hyperamylasemia associated with pancreatitis are pseudocysts, pancreatic trauma, and cholecodolithiasis. Pancreatic trauma can be the result of blunt trauma, abdominal or retroperitoneal surgery, or endoscopic retrograde pancreatic canal cannulation (ERCP). In patients with biliary colic-type abdominal pain, a threefold increase in serum amylase levels returns to normal within 48-72 hours. suggests the passage of a stone through the common bile duct [3,4]. Mumps due to infection, trauma or radiation is associated with an increase in type S isoamylase. Salivary gland damage can also occur as a consequence of chronic alcoholism. The level of amylase in saliva is three times higher than normal in 10% of patients treated for chronic alcoholism. It is also discussed that this phenomenon in alcoholics is a consequence of and / or liver damage because liver disease (hepatitis or cirrhosis) also shows elevated levels of isoamylases of type S and P [2].

Intestinal diseases (inflammatory bowel diseases, infarct mesentery, ileus, peritonitis) can lead to increased levels of pancreatic amylase. Ruptured ectopic pregnancy, ovarian cysts, or inflammation of the ovaries and fallopian tubes can result in elevated salivary isoamylase. Ectopic amylase production is possible in malignancies of the lungs, ovaries, pancreas, and colon; pheochromocytoma; team; multiple myeloma, breast cancer. Increases in amylase levels may occur postoperatively, after extracorporeal circulation or non-abdominal surgery (e.g., 30% of patients undergoing cardiac surgery have elevated type C isoamylase). Rare cases of hyperamylasemia have been reported with ciprofloxacin treatment. Other causes of hyperamylasemia include pneumonia, cerebral trauma, burns, abdominal aortic aneurysms, anorexia nervosa, and organophosphate poisoning. (5,6) Elevated pancreatic enzymes can be found in critically injured patients with trauma even if there is no true pancreatitis [1,2].

Macroamylasemia - Macroamylasemia is a rare, benign condition in which the amylase molecule binds to large complex molecules, reducing renal clearance and prolonging its half-life. The prevalence of macroamylasemia in the population is between 1 and 2%. About 2%-5% of patients with hyperamylasemia have macroamylasemia. Macroamylasemia is characterized by hyperamylasemia or elevated serum amylase levels without elevated urine amylase and other clinical signs or symptoms. In macroamylasemia, amylase is most often bound by immunoglobulin, making it 4 times larger than usual and the kidneys excrete it slowly and with difficulty, resulting in high serum amylase levels but normal urine levels [7-12]. In most cases, macromolecular amylase is a complex of normal amylase and immunoglobulin A or G. Different papers report different statistics on the incidence of macroamylasemia. It is most often present in adults (more often males), although cases have been reported in children and newborns. Elevated serum amylase levels are the main criterion for the diagnosis of pancreatitis. health system. This is important, among other things, because the main limitation of the use of serum amylase measurements in the diagnosis of the degree of pancreatitis is the lack of specificity of this test [1,7,13].

An accepted algorithm for the joint diagnosis of macroamylasemia, in elevated serum amylase without elevated urinary amylase, is subsequent serum lipase testing, which together with high amylase levels usually suggests pancreatitis [14]. If serum lipase is normal, renal function must be examined, because abnormal kidney function will also cause elevated amylase levels. Then when we conclude that renal function is normal, we should calculate the renal amylase clearance in relation to creatinine clearance - ACCR (Amylase-creatinine clearance ratio) according to the formula:

$$\text{ACCR} = \frac{\text{amyrase in urine}}{\text{serum amylase}} \times \frac{\text{serum creatinine}}{\text{creatinine in urine}} \times 100$$

The normal ratio of these clearance is between 3% and 5%, while a result of less than 1% suggests macroamylasemia [13]. The final confirmatory test is electrophoresis or polyethylene glycol precipitation test and chromatography [14]. As these are methods
CASE REPORT: Patient P.Ž. The 65-year-old comes for a gastroenterological examination on July 10, 2019, due to an occasional feeling of bloating in the abdomen and elevated serum amylase in the laboratory findings. The problems last from October 2018 and occur occasionally, approximately once in 7-10 days, usually after meals and discounts after bowel movements. It denies severe and hereditary diseases in personal and family history. He received symptomatic therapy (spasmolytics) which he used as needed. During the physical examination, an orderly objective finding is ascertained. In the laboratory reports that the patient brings - complete blood count, erythrocyte sedimentation rate, and C-reactive protein level were within the reference values.

Tumor marker CA19 / 9 was 31.6U / ml (normally up to 37 U/ml). Serum amylase levels were elevated - 235 IU / L (reference range: up to 100 IU / L). Other results in biochemical parameters, including serum lipase, nitrogen retention, aminotransferases, bilirubin, and serum iron were normal. Ultrasound and computed tomography of the abdomen showed a normal finding. An ultrasound examination of the neck (parotid gland region) is also normal.

Laboratory parameters were monitored after 3 months (30.10.2019) including erythrocyte sedimentation rate, CRP, lipase, aminotransferase, bilirubin and serum iron as well as anti-tissue transglutaminase-IgA (anti-tTG-IgA). All findings were within normal limits. Elevated serum amylase remained 197 IU / L. Urine amylase was also at reference values of 32 IU / L. We determined serum creatinine 75 umol / L and urine creatinine 7003 umol to calculate ACCR. The ACCR is 0.174.

Based on the clinical picture of the performed diagnosis and calculated ACCR, we conclude that it is very likely macroamylasemia. Definitive laboratory diagnosis by electrophoresis or polyethylene glycol precipitation test was not available to us and the patient was not motivated for additional diagnostics. (macrogol) as needed. The patient was examined after two months (December 25, 2019). He was without problems, the clinical findings were orderly. Serum amylase levels were 210 IU / L, urine amylase 45 IU / L. Due to the patient’s advanced age, lower digestive endoscopy was suggested, which the patient refused. A clinical control with new laboratory findings and an ultrasound examination of the abdomen is scheduled for 6 months. As the patient is older than 50, we anticipate monitoring the patient for another 1-2 years in order to definitely declare hyperamylasemia benign.

DISCUSSION:

Amylase is an enzyme responsible for the breakdown of amylase and other starches during digestion. It exists as three subtypes, where α-amylase is found in animals, including humans, and it is the only one of clinical importance [6]. Although hyperamylasemia is particularly associated with pancreatitis, there are other conditions and diseases that can occur with hyperamylasemia, including saladenitis, lung disease, ovarian cysts, ruptured ectopic pregnancy, abdominal trauma, mesenteric infarction, perforated peptic ulcer, appendicitis, renal failure, mumps, and some malignancies, all of which would require additional testing, unlike macroamylasemia [1,2,6,8,12].

Although macroamylasemia is mostly asymptomatic, diagnosis of this condition often begins with abdominal pain, including determination of serum and urine amylase. However, abdominal pain is not a symptom of macroamylasemia. It is usually just a coincidence, and amylase testing is often required when patients complain. to abdominal pain. According to one hypothesis, which has no confirmation, abdominal pain and macroamylasemia are detected together due to the deposition of macroamylase molecules in the pancreas [13], hematological malignancies [19,20] of systemic lupus erythematosus [21], rheumatoid arthritis [22] or celiac disease [23,24,25]. Several cases of celiac disease with macroamylasemia have been reported in which amylasemia has returned to normal after treatment with [26] Induced macroamylasemia has also been described, as shown by a study in which a group of subjects received infusions with a solution of hydroxyethyl starch (HES), a volemic colloid used in the treatment of hypovolaemia with HES solution Hyperamylasemia has been shown to be due to
macroamylase amylase complex and HES). As HES molecules disintegrated, hyperamylasemia or macroamylasemia resolved on their own. This study demonstrated that macroamylasemia may also have iatrogenic induction [13].

Other cases of asymptomatic hyperamylasemia have been reported in the literature, including chronic nonpathological hyperamylasemia of pancreatic origin, ethnic hyperamylasemia, and familial hyperamylasemia [27].

The theory of the formation of macro molecules of amylase is based on the "dysregulation" of immune tolerance, which can occur in immune disorders [28]. Cross-reactivity to either gluten or other antigens is thought to lead to the formation of autoantibodies against pancreatic serum amylase at the intestinal level. In this way, antibodies are formed, in most cases immunoglobulin A, rarely immunoglobulin G, which react with amylazoam to form immune complexes [29].

Almost all patients who have hyperamylasemia undergo expensive, long, difficult and often unnecessarily repeated diagnostic procedures. In one study that followed patients for 4 years, 60.7% of patients were diagnosed with chronic pancreatitis, 24.5% with recurrent pancreatitis and 13.7% had no specific diagnosis. After detailed clinical processing (serum Ca19-9 level, ultrasound abdomen, computed tomography and magnetic resonance imaging, endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography) in 35.2% of these patients it was concluded that it was macroamylasemia [30].

To avoid irrational diagnosis of elevated serum amylase in patients without clinical symptoms and symptoms, without elevated urinary amylase and normal serum lipase levels, renal function should be examined and renal amylase clearance calculated relative to creatinine clearance - ACCR at the beginning of the diagnostic program and assess the need for additional diagnostics. In that sense, the diagnostic algorithm of macroamylasemia, which dates back to 1989, is very practical. proposed by David LeVine and David Parrish [7].

THE PATIENT HAS AN INCREASED SERUM AMYLASE OVER 100 U/I

1. SERUM LIPLASE IS NORMAL
   - YES
   - NO
2. URINARY AMYLASE IS NORMAL OR REDUCED
   - YES
   - NO
3. RENAL FUNCTION IS NORMAL
   - YES
   - NO

4. 

\[
\frac{A_{\text{ser}}}{A_{\text{ur}} \times \frac{C_{\text{ser}}}{C_{\text{ur}}} \times 100 < 1}
\]

- YES
- NO
5. POSITIVE ELECTROPHORESIS
   - YES
   - NO

MACROAMYLASEMIA

Conclusion: In our patient, based on the clinical picture, performed diagnostics and calculated ACCR, we conclude that it is most likely macroamylasemia. These simple and inexpensive laboratory tests and calculations confirmed the diagnosis despite the lack of a
confirmatory laboratory test (Definitive diagnosis by electrophoresis or polyethylene glycol precipitation test was not available to us and the patient was not motivated for additional diagnosis). With the recommended diet and therapy, the patient was without any problems. Due to age, a colonoscopy was suggested, which the patient refused. A control clinical examination and ultrasound examination of the abdomen are scheduled for 6 months.

REFERENCES:

The diagnosis of macroamylasemia should be considered in the differential diagnosis of patients who have permanently elevated serum amylase, but do not show any characteristics of pancreatitis or inflammation of the salivary glands. ACCR can be a quick and inexpensive screening test to prevent unnecessary diagnosis and therapy.